AstraZeneca reaches PINNACLE only to point to greater COPD heights
This article was originally published in Scrip
AstraZeneca will file for approval of its combination product for chronic obstructive pulmonary disease (COPD) later this year on the back of positive top-line data from two studies in its Phase III PINNACLE program.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.